Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Company profile
Ticker
HTHO
Exchange
Website
CEO
Helen I. Torley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Microsoft • Oracle • Mobileye Global Inc - Ordinary Shares • Activision Blizzard • Gen Digital • Vmware • Adobe • Salesforce • BlackBerry • Dayforce ...
Former names
Abbott Mines LTD, Warp Technology Holdings Inc
SEC CIK
Corporate docs
IRS number
880467845
Latest filings (excl ownership)
RW
Registration withdrawal request
21 Dec 07
RW
Registration withdrawal request
19 Dec 07
15-12G
Securities registration termination
28 Sep 07
8-K
Bankruptcy or Receivership
21 Aug 07
8-K
Unaudited Pro Forma Consolidated Condensed Financial Statements
1 Jun 07
8-K
HALO Technology Holdings Announces Third Quarter Results
24 May 07
10QSB
2007 Q3
Quarterly report (small business)
21 May 07
10QSB/A
2007 Q2
Quarterly report (small business) (amended)
21 May 07
8-K
Entry into a Material Definitive Agreement
21 May 07
NT 10-Q
Notice of late quarterly filing
16 May 07
Latest ownership filings
144
Notice of proposed sale of securities
22 Apr 05
144
Notice of proposed sale of securities
21 Jan 05
144
Notice of proposed sale of securities
9 Sep 04
144
Notice of proposed sale of securities
7 Jun 04
144
Notice of proposed sale of securities
21 May 04
144
Notice of proposed sale of securities
20 May 04
144
Notice of proposed sale of securities
18 May 04
144
Notice of proposed sale of securities
23 Apr 04
144
Notice of proposed sale of securities
22 Apr 04
144
Notice of proposed sale of securities
20 Apr 04